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Abstract 21 
Background: Delayed-type β-lactam hypersensitivity develops in subset of patients. The 22 
cellular immunological processes that underlie the drug-specific response have been 23 
described; however, little is known about involvement of the humoral immune system. Thus, 24 
the aim of this study was to utilize piperacillin hypersensitivity as an exemplar to (1) develop 25 
cell culture methods for the detection of drug-specific B cell responses, (2) characterize drug-26 
specific IgG subtypes and (3) assess reactivity of IgG antibodies against proteins modified to 27 
different levels with piperacillin haptens.  28 
Methods: IgG secretion and CD19+CD27+ expression on B-cells were measured using 29 
ELIspot and flow cytometry, respectively. A Piperacillin-BSA adducts was used as an 30 
antigen in ELISA antibody binding studies. Adducts generated using drug:protein different 31 
ratios were used to determine the degree of conjugation required to detect IgG binding. 32 
Results: B-cells from hypersensitive patients, but not controls, were stimulated to secrete IgG 33 
and increase CD27 expression when cultured with soluble piperacillin. A piperacillin-BSA 34 
adduct with cyclized and hydrolyzed forms of the hapten bound to 8 lysine residues was used 35 
to detect hapten-specific IgG 1-4 subclasses in patient plasma. Hapten inhibition and the use 36 
of structurally unrelated hapten-BSA adducts confirmed antigen specificity. Antibody 37 
binding was detected with antigens generated at piperacillin:BSA ratios of 10:1 and above, 38 
which corresponded to a minimum epitope density of 1 for antibody binding.  39 
Conclusion: These data show that antigen-specific B-lymphocytes and T-lymphocytes are 40 
activated in piperacillin hypersensitive patients. Further work is needed to define the role 41 
different IgG subtypes play in regulating the iatrogenic disease.    42 
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Introduction 47 
Cystic fibrosis is a lethal autosomal recessive condition that leads to abnormal airway 48 
epithelial ion transport through mutations in a membrane-bound transporter. Recurrent 49 
infection develops as a consequence of mucus accumulation in the lungs. Repeated courses of 50 
long-term ß-lactam antibiotic are the cornerstone for management of respiratory 51 
exacerbations, but unfortunately their application is restricted due to delayed-type 52 
hypersensitivity reactions. Reactions develop at a higher frequency when compared to the 53 
general population (greater than 30% of adult patients with cystic fibrosis experience β-54 
lactam hypersensitivity) (1, 2). Patients present with rashes, fixed drug eruptions, arthralgia 55 
and drug fevers.  56 
β-lactam antibiotics interact with and bind covalently to specific lysine residues on protein 57 
generating an antigen that may activate cellular immune responses in susceptible patients. We 58 
have recently focused on three commonly used drugs in patients with cystic fibrosis, 59 
piperacillin, meropenem and aztreonam and found that each forms a distinct haptenic 60 
structure on albumin resulting in activation of drug-specific CD4+ T-lymphocytes isolated 61 
from hypersensitive patients (3-5). T-cell cross-reactivity with the different drugs was not 62 
observed. The absence of detectable drug-specific T-cells in tolerant patients exposed to 63 
several drug courses suggests that T-cells are directly involved in the disease pathogenesis.   64 
Drug protein adducts might also activate B-cells promoting hapten-specific immunoglobulin 65 
production (6-8). Once activated B-cells differentiate they are able to acquire a memory 66 
phenotype characterized by expression of cell surface receptors such as CD27+ (9). Memory 67 
B-cells reside primarily in peripheral blood and secrete immunoglobulin following re-68 
exposure to antigen. In vitro activation of memory B-cells following mitogen or specific 69 
antigen stimulation can be visualized using an IgG ELIspot or increases in CD27 expression 70 
(10, 11). Antigen-specific memory B-cells can be detected ex vivo in the presence or absence 71 
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of circulating serum IgG; hence, it is important to measure memory B-cell activation 72 
alongside serum antibodies to obtain a more detailed analysis of the antigen-specific humoral 73 
immune response.   74 
The role of humoral processes - specifically the activation of B-cells and involvement of IgG 75 
antibodies in piperacillin hypersensitivity - has not been delineated. Thus, the objectives of 76 
this study were to (1) develop cell culture methods for the detection of B-cell responses 77 
including IgG subclasses in piperacillin hypersensitive patients and (2) characterize 78 
piperacillin protein binding and assess the relationship between hapten density and antibody 79 
binding. 80 
 81 
 82 
  83 
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Methods 84 
Tissue culture reagents and antibodies. Culture medium for B-cell assays consisted of 85 
RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 0.001% 2-mercaptoethanol, 86 
100mM L-glutamine, 100 g/ml penicillin, and 100 U/mL streptomycin. FBS and human AB 87 
serum were purchased from GibCo, Life Technologies (Paisley, UK) and Innovative 88 
Research (Novi, MI, USA), respectively. All other culture reagents were purchased from 89 
Sigma-Aldrich (Poole, UK). CD3-fluorescein isothiocyanate (FITC), CD19-allophyco-cyanin 90 
(APC) and CD27-phycoerythrin (PE) antibodies used for flow cytometry were purchased 91 
from BD Biosciences (Oxford, UK).  92 
 93 
Patients Details. Patients were divided into three groups: piperacillin hypersensitive (n=3), 94 
piperacillin tolerant (n=3), and piperacillin naive (n=3) individuals. Hypersensitive patients 95 
developed maculopapular exanthema and in two cases drug-induced fever 2-9 days after 96 
initiation of piperacillin therapy. Number of courses prior to the reactions ranged from 3-9. 97 
The analyses were conducted 3-8 years after the reactions subsided. Patients were defined as 98 
hypersensitive following clinical diagnosis and a positive lymphocyte transformation test. 99 
Skin testing was not performed as previous studies show only 14% positivity in piperacillin 100 
hypersensitive patients with cystic fibrosis. Provocation tests are contraindicated. Tolerant 101 
patients had previously been exposed to several piperacillin courses with no noted adverse 102 
effects. Naïve patients had never been exposed to the drug. Written informed consent was 103 
obtained from all patients, and the study was approved by the Leeds East Ethics Committee. 104 
 105 
Peripheral blood mononuclear cell isolation and T-cell activation studies.  Peripheral 106 
blood mononuclear cells (PBMC) were isolated from whole blood using lymphoprep density 107 
gradient separation media (Axis Shield, Dundee, UK). Cells were suspended in B-cell culture 108 
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medium and processed as outlined below or T-cell culture medium for assessment of drug 109 
antigen-specific T-lymphocyte proliferative responses using the lymphocyte transformation 110 
test (12). Antigen-specific T-cell proliferative responses are presented as a stimulation index 111 
(SI; cpm in drug-treated cultures / cpm in control cultures), with an SI value  2 accepted as a 112 
positive response. 113 
 114 
B-cell activation studies. Solutions of CpG-DNA mitogen stimulation media and piperacillin 115 
were prepared in B-cell culture medium and transferred 48 well culture plates containing 116 
1x106 PBMC per well. Final concentrations of CpG-DNA and piperacillin were 1.5µg/ml and 117 
2mM, respectively. Plates were cultured for 5 days at 5% CO2/37C. PBMC were harvested 118 
on day 5 for IgG ELIspot analysis and assessment of CD19/CD27 expression by flow 119 
cytometry. Culture supernatant was harvested for assessment of secreted IgG by ELISA. 120 
Cells were stained with anti-CD3, CD19 and CD27 antibodies and analyzed using a Canto II 121 
flow cytometer (BD Biosciences) to assess the activation status of B-cells.  A minimum of 122 
50,000 cells were acquired using forward and side scatter characteristics. Data was analyzed 123 
using Cyflogic software (CyFlo, FL, USA). IgG release measured by ELIspot utilized the 124 
method developed by Crotty et al. (13) Spot forming units representing secreted IgG were 125 
visualized and analysed using an AID ELIspot plate reader (Autoimmun Diagnostika, DE). 126 
 127 
ELISA for quantification of total and drug-specific IgG in patient plasma and cell 128 
culture supernatant. Total IgG was measured by ELISA using a goat anti-human IgG antibody. 129 
To quantify anti-piperacillin-specific IgG, plates were coated overnight at 4°C with the 130 
piperacillin BSA adducts described below (20μg/ml; in 0.05M phosphate buffer, pH 7.2; 100 131 
l/well). After washing, patient plasma or culture supernatant was added for 1h. IgG 132 
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subclasses were quantified using horse radish peroxidase-labelled mouse anti human IgG1-4 133 
(Invitrogen) and NOR-01 human serum standard for IgG sub-classes (Nordic immunology).   134 
 135 
Preparation of piperacillin BSA adducts. To prepare adducted proteins, piperacillin was 136 
incubated with BSA in PBS at drug-protein ratios of 1:1, 5:1, 10:1, 20:1, 50:1, and 100:1 for 137 
24-96h at 37oC, pH 7.4. Incubations containing BSA alone were prepared and processed in 138 
the same way to generate an unmodified negative control. The extraction procedure is 139 
available in the supplementary methods.  140 
 141 
Mass spectrometric analysis of piperacillin BSA adducts. Trypsin was added to the 142 
piperacillin BSA adducts and the tubes were incubated at 370C for 24h. Piperacillin binding 143 
was initially quantified using Matrix assisted laser desorption ionisation (MALDI) mass 144 
spectrometry. Subsequent analysis used a QTRAP 5500 hybrid quadrupole-linear ion trap 145 
mass spectrometer (ABSciex) to analyse relative levels of piperacillin binding at each 146 
modified lysine residue.  MRM transitions specific for drug-modified peptides were selected 147 
as follows: the mass/charge ratio (m/z) values were calculated for all possible peptides with a 148 
missed cleavage at a lysine residue; to these were added the mass of the appropriate hapten 149 
(cyclised piperacillin, 517amu; hydrolysed piperacillin, 535amu); the parent ion masses were 150 
then paired with a fragment mass of 160 ([M+H]+ of cleaved thiazolidine ring) and/or a 151 
fragment mass of 106 ([M+H]+ of cleaved benzylamine group). Epitope profiles were 152 
constructed by comparing the relative intensity of MRM peaks for each of the modified 153 
lysine residues within a sample and normalization of those signals across samples. 154 
  155 
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Results 156 
Lymphocyte transformation test. Preliminary experiments utilized the lymphocyte 157 
transformation test to determine whether T-cells from hypersensitive and tolerant patients, as 158 
well as piperacillin naïve volunteers, are stimulated to proliferate in vitro in the presence of 159 
the drug. Proliferative responses above control values were observed when PBMC from all 3 160 
hypersensitive patients were cultured with piperacillin. Piperacillin-specific responses were 161 
dose-dependent with the strongest responses detected at concentrations of 1-2mM. The 162 
proliferative response tapered off at concentrations of 4mM and above (results not shown). 163 
Thus, 1-2mM piperacillin was selected for all subsequent experiments described below. 164 
PBMC from tolerant patients and piperacillin naïve volunteers were not activated in response 165 
to piperacillin (figure 1). 166 
 167 
Activation of B-lymphocytes following piperacillin and mitogen treatment. PBMCs 168 
isolated from each patient group were cultured with either mitogen or piperacillin for five 169 
days, after which CD19 and CD27 expression and IgG secretion were measured. A 170 
significant increase in cells staining postive for CD19 and CD27 was observed in all patients 171 
following mitogen treatment (P<0.05; figure 2). In contrast, an expansion of memory B-cells 172 
(CD19+CD27+) with piperacillin was only observed with PBMC from hypersensitive 173 
patients.   174 
PBMC (4-50x103) from naïve volunteers were used in preliminary experiments to determine 175 
the optimum conditions under which in vitro secretion of IgG from isolated B-cells could be 176 
detected using ELIspot. An increase in the number of IgG secreting cells was observed at 177 
each cell number when the mitogen-treated cells were compared to the negative control 178 
(results not shown). Experiments conducted with 2x104 PBMCS produced the most 179 
consistent results and as such, this cell number was used in all subsequent experiments with 180 
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PBMC from piperacillin naïve, tolerant and hypersensitive patients. As observed in the initial 181 
experiments, an increase in the number of IgG secreting cells was observed with PBMC from 182 
naïve volunteers and tolerant and allergic patients when mitogen-treated cells were compared 183 
to the negative control. Piperacillin-treated PBMC from hypersensitive patients also showed 184 
an increase in IgG secretion. In contrast, an increase in IgG secretion was not observed with 185 
PBMC from tolerant patients and healthy volunteers (figure 3A and B). Allergic patient 3 186 
donated blood on 4 separate occasions over an 18 month period and although the number of 187 
spot forming units varied in each experiment, piperacillin consistently stimulated an increase 188 
in IgG secretion when compared with the negative control (figure 3C).   189 
 190 
Piperacillin-specific IgG in hypersensitive patient plasma  191 
Unmodified BSA was found to show low absorbance values and hence piperacillin-BSA 192 
adducts were generated, characterized and used for the detection of piperacillin-specific IgG.   193 
SDS-PAGE western blot analysis of a piperacillin-BSA adduct, prepared using a 50:1 ratio of 194 
drug to protein, showed that drug binding was time-dependent with 96h shown to be the 195 
optimum time for adduct formation (figure 4A). Mass spectrometric analysis identified the 196 
characteristic fragment ions m/z 160 and 143 (figure 4B). Piperacillin haptens were detected 197 
on 8 of the 13 lysine residues modified in HSA (figure 4C). Relative levels of modification at 198 
each lysine residue are shown in figure 4D.  199 
Anti-piperacillin-specific IgG was detected in plasma of each hypersensitive patient at levels 200 
ranging from 500 to 3000ng/ml (figure 5A). In each case, the addition of an excess of 201 
piperacillin to plasma prevented piperacillin-BSA IgG binding. Anti-piperacillin-specific IgG 202 
was not detected in plasma from either drug tolerant patients or naïve volunteers.   203 
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p-Phenylenediamine- and isoniazid-BSA adducts were prepared according to methods of 204 
Jenkinson et al. and Meng et al. (14, 15) respectively to confirm the specificity of 205 
piperacillin-specific IgG.  An increase in absorbance readings was not observed when 206 
piperacillin hypersensitive patient plasma was added to ELISA plates coated with p-207 
phenylenediamine or isoniazid-BSA adducts (Figure 5B).  208 
To determine whether our findings with 3 hypersensitive patients are representative of 209 
piperacillin hypersensitive patients in general, plasma from 12 lymphocyte transformation 210 
test positive patients and 9 drug tolerant controls (Figure 5D) was used to quantify 211 
piperacillin-specific IgG by ELISA. Piperacillin-specific IgG was detected in 9 212 
hypersensitive patients. In contrast, plasma form only one tolerant control displayed low 213 
levels of piperacillin-specific IgG (Figure 5C). A weak correlation between lymphocyte 214 
proliferation and levels of piperacillin-specific IgG in plasma was observed (Figure 5E); 215 
however, the data is somewhat skewed by data from one patient with the strongest 216 
lymphocyte proliferation data.         217 
 218 
IgG sub-class analysis in allergic patient plasma 219 
 220 
There are 4 classes of IgG: IgG1 (60-65%; approximate abundance in humans), IgG2 (20-221 
25%), IgG3 (5-10%) and IgG4 (4%) (16-19). IgG subclass analysis of total IgG in plasma 222 
from piperacillin hypersensitive patients revealed the expected profile with antibody classes 223 
in the order of IgG1 > IgG2 > IgG3 > IgG4 (figure 5F). The piperacillin-BSA adduct 224 
described above was used as an antigen to assess the IgG subclasses with specificity for 225 
piperacillin. Anti-piperacillin specific IgG expression seemed to showed a bias for IgG2 over 226 
other subclasses; IgG1 and IgG2 were expressed at approximately the same level in 5 out of 6 227 
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hypersensitive patients (figure 5G). The ratio of piperacillin specific IgG sub-classes in 1 228 
patient was similar to that seen with total IgG. 229 
 230 
Hapten density-dependent binding of piperacillin-specific antibodies to BSA adducts  231 
Piperacillin-BSA adducts with various hapten densities were synthesized by incubating 232 
piperacillin with BSA at molar ratios of 1:1, 5:1, 10:1, 20:1, 50:1 and 100:1 for 96h. SDS-233 
PAGE analysis of the adducts revealed bands of increasing intensity at 66 kDa as the 234 
concentration of piperacillin was increased (figure 6A). The relative level of piperacillin 235 
binding at each of the 8 modified lysine residues (Lys 4, 12, 132, 136, 211, 221, 431, and 236 
524) is shown in figure 6B. The level of binding increased with increasing piperacillin 237 
concentration at each site of modification (figure 6B). However, the highest ion counts were 238 
consistently detected with the peptide containing Lys 431 (figure 6C). An increase in the total 239 
number of sites modified with piperacillin was not observed as the drug:protein ratio 240 
increased. MALDI-TOF analysis showed the corresponding masses of the different adducts 241 
generated. The mass values were used to estimate the density of the piperacillin hapten bound 242 
to BSA (figure 6D).  243 
Plasma samples from the hypersensitive patients were then used to explore the influence of 244 
hapten density on piperacillin-specific IgG binding. A direct correlation between hapten 245 
density and IgG binding was observed (r2=0.9574). Piperacillin-specific IgG binding was 246 
observed with antigen generated using drug:protein ratios of 10:1 and above (figure 6E).  247 
 248 
 249 
  250 
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Discussion 251 
β-lactam antibiotics are a common cause of delayed-type hypersensitivity. Drug binding to 252 
protein lysine residues is believed to represent the principal initiating event for activation of 253 
an immune response and tissue injury in susceptible patients. Mass spectrometry has 254 
previously been used to characterize the nucleophilic targets on HSA for β-lactam hapten 255 
binding in patients (5, 20, 21).  Subsequently, synthetic β-lactam HSA adducts with the drug 256 
hapten bound to the lysine residues modified in vivo were used as an antigen in in vitro T-cell 257 
assays. The adduct was found to activate PBMC and T-cell clones from hypersensitive, but 258 
not tolerant, patients to proliferate and secrete cytokines via a pathway dependent on protein 259 
processing by antigen presenting cells (4, 5, 22). Hence, hapten-specific T-cells and the 260 
effector molecules they secrete are thought to be responsible for the initiation and regulation 261 
of delayed-type β-lactam reactions. β-lactam protein adducts also activate a humoral response 262 
in hypersensitive patients;6-8 however, investigation of the nature of the response has been 263 
knowingly or otherwise neglected. Thus, the objective of this study was to characterize drug-264 
specific B-cell responses in hypersensitive patients, analyze whether drug-specific IgG 265 
circulates in plasma and explore the relationship between hapten density and IgG binding. 266 
Piperacillin hypersensitive patients with cystic fibrosis were selected as the study cohort since 267 
the piperacillin HSA binding interaction and the drug hapten-specific cellular response has 268 
been characterized previously (3-5). 269 
Initially, the lymphocyte transformation test was used to confirm the presence of drug-270 
responsive T-cells in hypersensitive patients. PBMC from all 3 hypersensitive patients were 271 
stimulated to proliferate in vitro in a concentration-dependent manner. In contrast, T-cells 272 
from tolerant patients and drug-naïve volunteers were not activated with piperacillin.  To 273 
detect a B-cell response to piperacillin, PBMC from each patient group were cultured with 274 
the drug for 5 days prior to the detection of specific B-cell activation markers by flow 275 
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cytometry and IgG secretory profiles by ELISpot. CpG-dna was selected as a positive control 276 
because of its propensity to activate immature and mature B cells via TLR9 stimulation (23) 277 
leading to both cell proliferation and IgG production (24).  278 
Memory B-cells with the ability to synthesize and rapidly secrete immunoglobulins can be 279 
differentiated from their naïve counterparts by enhanced expression of CD27+ (9, 25). Thus, 280 
CD27 was used as a marker on CD19+ B-cells to quantify the number of memory B-cells 281 
after incubation of PBMC with piperacillin or CpG-dna. Flow cytometric assessment of 282 
PBMC from hypersensitive patients showed an increase in expression of CD27+ on B-cells in 283 
response to piperacillin (and mitogen) treatment. In contrast, a piperacillin-specific increase 284 
in CD27 expression was not observed on cells from tolerant patients or healthy donors. This 285 
data is in agreement with previous studies that shows an increase in the number of memory B 286 
cells in patients infected with Schistosoma Haematobium (26). Piperacillin treatment of 287 
PBMC from hypersensitive patients also led to an increase in the secretion of IgG, visualized 288 
using a memory B-cell ELIspot assay established by Crotty et al (13). However, no difference 289 
in IgG secretion was observed with PBMC from tolerant patients and naïve volunteers after 290 
drug treatment. Collectively, these data indicate that piperacillin-responsive memory B-cells 291 
circulate in peripheral blood of hypersensitive, but not tolerant, patients for multiple years 292 
after the initial exposure.  293 
ELISA has proved useful in both the detection and assessment of antibody responses against 294 
protein and drug antigens (6, 27, 28). A piperacillin-BSA adduct was generated and 295 
employed as an antigen in a hapten-inhibition ELISA for unambiguous analysis of IgG 296 
specific to piperacillin. As described in our previous study using HSA as a protein carrier (5), 297 
piperacillin formed archetypal adducts on lysine residues of BSA through opening of the β-298 
lactam ring. Moreover, an additional hapten structure was detected in which the 2,3-299 
dioxopiperazine ring had undergone hydrolysis. Modification of 8 lysine residues were 300 
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detected on BSA under the experimental conditions used to generate an antigen (50:1 301 
piperacillin:BSA, 96h incubation) for immunochemical detection of piperacillin-specific IgG. 302 
Each site of modification paralleled a piperacillin-modified lysine residue on HSA, further 303 
highlighting the acute specificity of the binding interaction to hydrophobic pockets in the 304 
protein that have previously been shown to be involved in the non-covalent docking of low 305 
molecular weight compounds (29, 30). Hapten inhibitable anti-drug antibodies specific to 306 
piperacillin were detected in plasma from the hypersensitive patients. This data suggests that 307 
the IgG circulating in hypersensitive patient plasma exhibits specificity for the piperacillin 308 
hapten. This was confirmed through (1) the generation of BSA adducts using structurally 309 
unrelated chemical (p-phenylenediamine) and drug (isoniazid) haptens and assessment of IgG 310 
binding and (2) analysis of a larger patient cohort. IgG circulating in piperacillin 311 
hypersensitive patients did not bind to either p-phenylenediamine or isoniazid protein 312 
adducts. However, piperacillin-specific IgG was detected in 9/12 piperacillin lymphocyte 313 
transformation test positive patients, but only 1/9 piperacillin tolerant controls.  314 
To explore the impact of the carrier protein on the detection of piperacillin-specific IgG, 315 
piperacillin human serum albumin and piperacillin lysozyme adducts were generated and 316 
characterized in terms of relative levels of lysine modification.  Unfortunately, IgG 317 
quantification experiments were hindered by high levels of non-specific binding associated 318 
with the use of the protein carrier alone. Thus, future studies should attempt to identify 319 
alternative protein carriers to determine the importance of the protein structure in antibody 320 
binding. Piperacillin hapten-specific IgG was not detected in plasma of naïve volunteers, 321 
whereas low levels were found in 1 tolerant control.  322 
The previously described profile of total IgG subclasses (IgG1>IgG2>IgG3>IgG4) was 323 
detected in hypersensitive and tolerant patient plasma. A similar analysis of piperacillin 324 
hapten-specific IgG showed a bias for IgG2 over other subclasses in 5/6 of the hypersensitive 325 
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patients. An increased susceptibility to certain bacterial infections is related to a deficiency in 326 
IgG2, signifying a role for IgG2 in combating bacterial pathogens (31). Moreover, patients 327 
with immediate allergic reactions to food have been shown to have significantly raised levels 328 
of antigen-specific IgG2 (32).    329 
The ratio at which drugs and proteins are conjugated has previously been shown to influence 330 
the nature of the antibodies induced by the hapten, with an increase in epitope density usually 331 
bringing about an increase in the strength and specificity of the immune response. Therefore, 332 
the final component of our study was directed towards investigating the relationship between 333 
piperacillin hapten density and antibody binding. A range of piperacillin-BSA adducts were 334 
generated at a drug:protein ratio of  1:1-100:1. MALDI-TOF analysis showed that the number 335 
of piperacillin molecules bound to BSA increased in a linear fashion with an increase in the 336 
piperacillin:BSA ratio. Based on the molecular mass of the adducts, it was possible to 337 
estimate that the hapten density ranged from 0.4-3.7 (molecules of piperacillin bound 338 
covalently to each molecule of BSA). As expected, the relative level of binding increased at 339 
each modified lysine residue with increasing concentrations of piperacillin. Antibody binding 340 
was initially detectable using an adduct generated at a ratio of 10:1 piperacillin:BSA, which 341 
corresponded to an epitope density of approximately 1. The extent of antibody binding then 342 
escalated in an incremental fashion with an increase in the epitope density (r2 = 0.9574).  343 
To conclude, our data shows the activation of hypersensitive patient B-cells with piperacillin. 344 
The presence of circulating piperacillin-specific IgG was detected in 9/12 patients with a 345 
positive lymphocyte transformation test, but only 1/9 tolerant controls. Thus, future studies 346 
should investigate how antibodies interact with T-cells (1) during the pathogenic response 347 
and (2) in patients undergoing desensitization with piperacillin.  Furthermore, it would be 348 
interesting to explore whether the methods developed here could be used to detect other 349 
classes of piperacillin-specific antibody.   350 
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Figure legends 372 
Figure 1. Piperacillin-specific proliferation of PBMC from hypersensitive and tolerant 373 
patients and healthy volunteers. PBMCs (1.5×105 cells in 100 μL) were incubated with 374 
graded concentrations of piperacillin (0.5-2mM in 100 μL) in 96-well U-bottom plates. Plates 375 
were incubated at 37°C under an atmosphere of 5% CO2 for five days. [
3H]-thymidine 376 
(0.5μCi/well) was added for the final 16h of incubation and T-cell proliferation measured 377 
using scintillation counting with a Beta counter. The data was analysed by Students T-test 378 
with p < 0.05 considered significant. 379 
 380 
Figure 2. CD27+ expression on piperacillin treated B-cells of hypersensitive and 381 
tolerant patients and healthy volunteers. PBMCs (1x106/ 1ml) were cultured in 24 well 382 
flat-bottomed plates with piperacillin (1-2mM) and CpG-DNA (1.5µg/ml) for 5 days. CD27+ 383 
expression was measured by flow cytometry. (A) Comparison of normalized results from 384 
hypersensitive and tolerant patients and healthy volunteers. (B) Number of hypersensitive 385 
patient CD19+ cells that express CD27 with and without treatment. (C) Representative flow 386 
cytometry images.   387 
 388 
Figure 3. Piperacillin-specific IgG secretion from B-cells of hypersensitive and tolerant 389 
patients and healthy volunteers. PBMCs (1x106/ 1ml) were cultured in 24 well flat-390 
bottomed plates with piperacillin (1-2mM) and CpG-DNA (1.5µg/ml) for 5 days. (A) 391 
ELIspot plates were pre-coated with anti-human IgG incubated overnight at 4oC. PBMCs 392 
were harvested and 5x104 transferred to each well and incubated for 48 hours. ELIspot plates 393 
were developed according to the manufacturer’s instructions. Data was analysed using an 394 
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AID ELIspot reader. Bar charts show results from individual patients. (B) Representative 395 
images from a tolerant and hypersensitive patient and a healthy volunteer. (C) 396 
Reproducibility of the ELIspot data using hypersensitive patient 3 PBMC isolated from 4 397 
separate blood donations over a 2 year period. The data was analysed by Students T-test with 398 
p < 0.05 considered significant. 399 
 400 
Figure 4. Characterization of the piperacillin-BSA antigen. Piperacillin and BSA were 401 
incubated at a molar ratio of 50:1 for 24 or 96 hours at 37oC. Unmodified drug was removed 402 
prior to analysis using immunochemical and mass spectrometric methods. (A) Unmodified 403 
and piperacillin-modified BSA were run on SDS-PAGE and blotted onto a nitrocellulose 404 
membrane.  The membrane was blocked with 2.5 % milk and incubated overnight at 4oC with 405 
a monoclonal mouse anti-penicillin antibody. After washing, the membrane was incubated 406 
with goat anti-mouse HRP-conjugated secondary antibody prior to ECL development with 407 
photographic film. (B) Representative MRM spectral image of a BSA peptide containing a 408 
piperacillin-modified lysine residue and chemical structure of the cyclized and hydrolyzed 409 
forms of the piperacillin hapten bound covalently to BSA. Spectral images show piperacillin 410 
modification on Lys190 showing with the characteristic fragment ions at m/z 160 and 143. 411 
(C) Table showing the triptic peptide sequences containing lysine residues in BSA modified 412 
by piperacillin. Mass spectrophotometry was used to characterize the sites of modification. 413 
(D) Epitope profile showing the lysine residues of BSA modified with the cyclized and 414 
hydrolysed piperacillin haptens. Graphs show all 13 piperacillin binding sites in HSA. 415 
 416 
Figure 5.  Detection of piperacillin-specific IgG in plasma of hypersensitive and tolerant 417 
patients and healthy volunteers. (A) Detection of piperacillin-specific IgG (Mean ± SD) by 418 
19 
 
ELISA from each patient group (n=3 per group). An aliquot of plasma was pre-incubated 419 
with an excess of piperacillin for analysis of hapten inhibition.  (B) Detection of IgG binding 420 
to structurally unrelated chemical and drug antigens using plasma from hypersensitive 421 
patients. Results presented as mean ± SD (n=3 per group). (C) Expression of piperacillin-422 
specific IgG in plasma of 12 lymphocyte transformation test positive patients. Each data point 423 
shows ng/ml in patient plasma with plasma + hapten inhibition subtracted. (D) Maximum 424 
lymphocyte transformation test result with PBMC from patients in (C). Each coloured 425 
symbol shows results from one patient. (E) Correlation of piperacillin-specific PBMC 426 
proliferation with detection of specific IgG in plasma. (F) Expression of total IgG sub-classes 427 
in plasma of patients. (G) Expression of piperacillin-specific IgG sub-classes in 6 428 
hypersensitive patients. Colour coding does not refer to the same patients shown in (C) and 429 
(D). Data was analysed by the Students T test to compare the difference between means.   430 
p≤0.05 considered as significant. 431 
 432 
Figure 6. Piperacillin-specific IgG binding to antigens with different epitope profiles. 433 
Piperacillin and BSA were incubated at ratios of 1:1, 5:1, 10:1, 20:1, 50:1 and 100:1 434 
(piperacillin:BSA) for 96h at 37oC. Free drug was removed and adducts characterized using 435 
immunochemical and mass spectrometric methods. (A) Western blot and an anti-penicillin 436 
mouse monoclonal antibody were used to show the dose-dependent binding of piperacillin to 437 
BSA. (B) Concentration-dependent increase in piperacillin hapten binding (cyclyzed and 438 
hydrolysed forms combined) at each modified lysine residue of the piperacillin-BSA antigens 439 
generated using different molar ratios of drug:protein. (C) Epitope profiles of the piperacillin-440 
BSA antigen generated using different molar ratios of drug:protein. (D) Quantification of 441 
piperacillin-BSA antigen. The observed molecular mass values from the MALDI - TOF was 442 
obtained, and these values were used to determine the mass variations detected. The ratio of 443 
20 
 
the variations to the molecular mass of piperacillin (∆M/Mh) produced the hapten density. 444 
(E) IgG antibody binding to the different piperacillin-BSA antigens. Plasma from 445 
hypersensitive patients was incubated with the plate bound antigens and the level of binding 446 
quantified using ELISA. Data was analysed by the Students T test to compare the difference 447 
between means with p≤0.05 considered as significant. 448 
 449 
  450 
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